Search Results
Aug 06, 2026, 06:00 ET Vision Marine Technologies Appoints Lakshmi Rampersaud as General Manager of Nautical Ventures Group
company, today announced the appointment of Lakshmi Rampersaud as General Manager of its subsidiary, Nautical Ventures Group Inc. ("Nautical Ventures" or "NVG").
More news about: Vision Marine Technologies, Inc
Jul 13, 2026, 16:58 ET Vision Marine Technologies Delivers 27% Sequential Q3 Revenue Growth
contribution from the acquisition of NVG.Third-quarter revenue was $18.4 million, an increase of approximately 27% from $14.5 million in the second quarter of fiscal 2026 in the third quarter of fiscal 2025. The year-over-year increase primarily reflects the inclusion of NVG following its acquisition in
More news about: Vision Marine Technologies, Inc
Jun 18, 2026, 10:01 ET Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight
biologics, and the anticipated introduction of novel mechanism-based therapies such as Riliprubart (Sanofi), Batoclimab (Immunovant), Empasiprubart (argenx), NVG-2089 (Nuvig Therapeutics), DNTH103 (Dianthus Therapeutics), TAK-881 and TAK-411 (Takeda), and others.LAS
More news about: DelveInsight Business Research, LLP
May 28, 2026, 10:01 ET Immune Thrombocytopenia Market Forecast Signals Steady Growth During the Forecast Period (2026-2036) Backed by Pipeline Advancements | DelveInsight
Biopharma) Mezagitamab (Takeda), PF-06835375 (Pfizer), Cevidoplenib (Genosco and Oscotec), RAY121 (Roche/Chugai Pharmaceutical), Efgartigimod (argenx), NVG-2089 (Nuvig Therapeutics), and others with better safety and efficacy profiles is further fueling market expansion.LAS
More news about: DelveInsight Business Research, LLP
May 07, 2026, 07:05 ET REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
diseases, and highlight the company's unique capsid engineering and translational capabilities.Title: NVG82, a capsid engineered for enhanced outer retinal gene transfer when administered in the suprachoroidal space, demonstrates superior on-target activity
More news about: REGENXBIO Inc.
Apr 15, 2026, 06:00 ET Vision Marine Technologies Accelerates Operational Transformation with NVG Segment Near EBITDA Breakeven and Significant Balance Sheet Improvements
the acquisition of NVG on June 20, 2025, the Company has delivered substantial improvements in working capital efficiency, leverage reduction, and operating performance, positioning NVG near EBITDA breakeven within less than one year of integration.Key Achievements at NVG Segment Since Acquisition
More news about: Vision Marine Technologies, Inc
Jan 27, 2026, 08:15 ET One Year After DCA Midair Disaster, Families Fight for Accountability
the U.S. Army and its 12th Aviation Battalion caused or contributed to the collision by permitting PAT25 to conduct a nighttime night vision goggle (NVG) training mission in DCA's congested airspace without actively transmitting its position, then requesting and accepting visual separation and failing
More news about: Wisner Baum
Jan 13, 2026, 08:45 ET Vision Marine Technologies Reports $1.9 Million of Cash Provided by Operating Activities in First Quarter of Fiscal 2026
following a period in which operations had historically consumed cash. This quarter reflects the early stages of integrating Nautical Ventures Group Inc. ("NVG" or "Nautical Ventures") and the initial implementation of operating efficiencies and organizational alignment, which are only beginning. We are striving
More news about: Vision Marine Technologies, Inc
Oct 16, 2025, 17:31 ET Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight
Additionally, the launch of therapies such as AZD0486 (AstraZeneca), EO2463 (Enterome), Abexinostat (Xynomic Pharmaceuticals), ZE50-0134 (Eilean Therapeutics), NVG-111 (NovalGen), and others will further fuel the market.
More news about: DelveInsight Business Research, LLP